NovaBay Pharmaceuticals (NYSE:NBY) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Thursday morning. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets lowered their target price on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a report on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

Shares of NYSE NBY opened at $0.53 on Thursday. NovaBay Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $9.10. The firm has a 50-day moving average of $0.63 and a 200 day moving average of $1.05. The stock has a market cap of $2.60 million, a P/E ratio of -0.01 and a beta of 0.69.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.